Tempest Therpeutics Inc (TPST) Quote

TPST...$1.80...setting up Reversal Candle here...adding...🥳

Yup...nice buy for the CEO...🥳

TPST...$2.14...adding down here...🥳

Form 4

TPST...$2.25s clearing here...🥳

TPST...$2.18...Forming a Bullish Engulfing Candle...🥳

fucking turds

Lol offering upsized right after the news..

in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.

yup and time to go up even more let's pass 7 and up trmw

UPstink today

TPST under $4

El stinko day today

Any other bio cheapies besides hook

Was that you 3.12 big

OUT AT 3.53:))))

$3.43:))))

FROM 2.92 MY CALL.NOW 3.38:))))

AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.

ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))

This is their reload zone evidently..price going higher

Under 15min remaining for them to fake-volume trade this..lol

Price rising with volume

Wonder which partner Tempest selects for its TPST treatment.

“Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”

20k share trade at $3.42

Grabbed $3.50’s..should find out who they partnered with..soon enough

Grabbed some $3.70’s for next run over $5

Must be todays conference causing rally

Up 13%

Up 12% 2nd million..let’s see 3rd

Very Nice !!

Looks ready!!

Up 7% 1st million volume..let’s see after 2nd

Yall musta seen 911 trade..bout40min before $3.80’s breakout l..yesterday

Yall arent very good@what yall do..still got all-my shares

Yep

Bulls taking control premarket evidently

16,745 share trade at $3.83

“Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference”

News out or market just happy to see me?

All Aboard!!!

$5 would be nice

$4’s and $5’s this week?

TPST$$$$$
LETS GET IT.

Looking great today!!!

Y’all aren’t very good at what y’all do lol

Y’all gave up too many shares…now I’ve got more.

Inherent risk in industry..temporary

THIS POS IS LOSING AN ENORMOUS AMOUNT OF MONEY.IT SHOULD BE TRADING IN THE .30 AREA.MAX.
Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
•
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
•
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
•
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.


Year-to-Date

•
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
•
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
•
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.